
    
      This is a multicenter, randomized, controlled, phase II study assessing the efficacy and
      safety of Almonertinib versus Paclitaxel Plus Carboplatin as first-line treatment in patients
      with EGFR mutation positive locally advanced or metastatic Pulmonary Adenosquamous Carcinoma.
      Eligible patients will be randomized to receive either Almonertinib (110mg, po, once daily)
      or paclitaxel (175mg/m2, iv) plus carboplatin (AUC=5, iv) in a 1:1 ratio.
    
  